Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 22.28% is in line with its 5-year average of 20.56%, near the high end of its 5-year range (10.54%–22.63%).
As of the fiscal period ended Tuesday, June 30, 2026. 3.45% above its 12-month average of 21.54%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
RETURN ON EQUITY (ROE)
22.28%
RETURN ON EQUITY (ROE) AVG TTM
21.54%
RETURN ON EQUITY (ROE) AVG 3Y
21.22%
RETURN ON EQUITY (ROE) AVG 5Y
20.56%
RETURN ON EQUITY (ROE) AVG 10Y
13.45%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+3.45%
CURRENT VS 3Y AVG
+4.99%
CURRENT VS 5Y AVG
+8.38%
CURRENT VS 10Y AVG
+65.71%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
13.01%
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
+71.27%
vs the sector median at left
IQVIA Holdings Inc.
Market Cap
$42.05B
Return on Equity (ROE)
22.28%
TTM Avg
21.54%
3Y Avg
21.22%
5Y Avg
20.56%
Market Cap
$42.85B
Return on Equity (ROE)
9.10%
TTM Avg
-6.34%
3Y Avg
-12.86%
5Y Avg
-14.53%
Market Cap
$41.06B
Return on Equity (ROE)
70.67%
TTM Avg
60.82%
3Y Avg
72.53%
5Y Avg
81.69%
Market Cap
$40.91B
Return on Equity (ROE)
19.56%
TTM Avg
20.59%
3Y Avg
21.51%
5Y Avg
20.54%
Market Cap
$47.93B
Return on Equity (ROE)
6.65%
TTM Avg
7.05%
3Y Avg
11.93%
5Y Avg
15.09%
Market Cap
$49.69B
Return on Equity (ROE)
3.85%
TTM Avg
6.60%
3Y Avg
6.50%
5Y Avg
6.42%
Market Cap
$49.83B
Return on Equity (ROE)
9.46%
TTM Avg
26.07%
3Y Avg
24.86%
5Y Avg
23.86%
Market Cap
$34.07B
Return on Equity (ROE)
59.67%
TTM Avg
-187.43%
3Y Avg
134.89%
5Y Avg
51.69%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IQVIA Holdings Inc. (IQV) | $42.05B | 22.28% | 21.54% | 21.22% | 20.56% |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $42.85B | 9.10% | -6.34% | -12.86% | -14.53% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $41.06B | 70.67% | 60.82% | 72.53% | 81.69% |
| Agilent Technologies, Inc. (A)vs › | $40.91B | 19.56% | 20.59% | 21.51% | 20.54% |
| Humana Inc. (HUM)vs › | $47.93B | 6.65% | 7.05% | 11.93% | 15.09% |
| Becton, Dickinson and Company (BDX)vs › | $49.69B | 3.85% | 6.60% | 6.50% | 6.42% |
| Edwards Lifesciences Corporation (EW)vs › | $49.83B | 9.46% | 26.07% | 24.86% | 23.86% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $34.07B | 59.67% | -187.43% | 134.89% | 51.69% |
| Alcon Inc. (ALC)vs › | $33.58B | 2.96% | 4.58% | 3.90% | 2.45% |
| DexCom, Inc. (DXCM)vs › | $31.99B | 38.14% | 28.93% | 25.01% | 22.95% |
ROE
22.3%
ROA
4.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 22.28% |
| 2026-03-31 | 22.26% |
| 2025-12-31 | 20.91% |
| 2025-09-30 | 20.83% |
| 2025-06-30 | 21.41% |
| 2025-03-31 | 22.32% |
| 2024-12-31 | 22.63% |
| 2024-09-30 | 20.17% |
| 2024-06-30 | 21.19% |
| 2024-03-31 | 21.39% |
| 2023-12-31 | 22.22% |
| 2023-09-30 | 19.22% |
| 2023-06-30 | 19.07% |
| 2023-03-31 | 17.78% |
| 2022-12-31 | 18.92% |
| 2022-09-30 | 22.11% |
| 2022-06-30 | 21.67% |
| 2022-03-31 | 18.23% |
| 2021-12-31 | 15.99% |
| 2021-09-30 | 13.16% |
| 2021-06-30 | 10.54% |
| 2021-03-31 | 6.87% |
| 2020-12-31 | 4.65% |
| 2020-09-30 | 3.01% |
| 2020-06-30 | 2.36% |
| 2020-03-31 | 3.88% |
| 2019-12-31 | 3.18% |
| 2019-09-30 | 3.98% |
| 2019-06-30 | 3.79% |
| 2019-03-31 | 3.75% |
| 2018-12-31 | 3.86% |
| 2018-09-30 | 17.55% |
| 2018-06-30 | 17.57% |
| 2018-03-31 | 15.80% |
| 2017-12-31 | 16.03% |
| 2017-09-30 | 0.63% |
| 2017-06-30 | 0.77% |
| 2017-03-31 | 1.08% |
| 2016-12-31 | 1.33% |
